Operating Lease, Right-of-Use Asset of BRAINSTORM CELL THERAPEUTICS INC. from 31 Dec 2018 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
BRAINSTORM CELL THERAPEUTICS INC. quarterly Operating Lease, Right-of-Use Asset in USD history and change rate from 31 Dec 2018 to 30 Sep 2025.
  • BRAINSTORM CELL THERAPEUTICS INC. Operating Lease, Right-of-Use Asset for the quarter ending 30 Sep 2025 was $334,000, a 65% decline year-over-year.
Source SEC data
View on sec.gov
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Change (%)

BRAINSTORM CELL THERAPEUTICS INC. Quarterly Operating Lease, Right-of-Use Asset (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $334,000 -$625,000 -65% 30 Sep 2025 10-Q 14 Nov 2025 2025 Q3
Q2 2025 $495,000 -$615,000 -55% 30 Jun 2025 10-Q 14 Aug 2025 2025 Q2
Q1 2025 $653,000 -$612,000 -48% 31 Mar 2025 10-Q 15 May 2025 2025 Q1
Q4 2024 $807,000 -$609,000 -43% 31 Dec 2024 10-Q 14 Nov 2025 2025 Q3
Q3 2024 $959,000 -$2,411,000 -72% 30 Sep 2024 10-Q 14 Nov 2024 2024 Q3
Q2 2024 $1,110,000 -$2,603,000 -70% 30 Jun 2024 10-Q 14 Aug 2024 2024 Q2
Q1 2024 $1,265,000 -$2,789,000 -69% 31 Mar 2024 10-Q 14 May 2024 2024 Q1
Q4 2023 $1,416,000 -$2,973,000 -68% 31 Dec 2023 10-K 31 Mar 2025 2024 FY
Q3 2023 $3,370,000 -$1,356,000 -29% 30 Sep 2023 10-Q 14 Nov 2023 2023 Q3
Q2 2023 $3,713,000 -$1,343,000 -27% 30 Jun 2023 10-Q 14 Aug 2023 2023 Q2
Q1 2023 $4,054,000 -$1,326,000 -25% 31 Mar 2023 10-Q 15 May 2023 2023 Q1
Q4 2022 $4,389,000 -$392,000 -8.2% 31 Dec 2022 10-K 01 Apr 2024 2023 FY
Q3 2022 $4,726,000 -$612,000 -11% 30 Sep 2022 10-Q 14 Nov 2022 2022 Q3
Q2 2022 $5,056,000 -$830,000 -14% 30 Jun 2022 10-Q 15 Aug 2022 2022 Q2
Q1 2022 $5,380,000 -$1,046,000 -16% 31 Mar 2022 10-Q 16 May 2022 2022 Q1
Q4 2021 $4,781,000 -$2,091,000 -30% 31 Dec 2021 10-K 30 Mar 2023 2022 FY
Q3 2021 $5,338,000 +$3,961,000 +288% 30 Sep 2021 10-Q 15 Nov 2021 2021 Q3
Q2 2021 $5,886,000 +$4,237,000 +257% 30 Jun 2021 10-Q 05 Aug 2021 2021 Q2
Q1 2021 $6,426,000 +$4,509,000 +235% 31 Mar 2021 10-Q 26 Apr 2021 2021 Q1
Q4 2020 $6,872,000 +$4,690,000 +215% 31 Dec 2020 10-K 28 Mar 2022 2021 FY
Q3 2020 $1,377,000 -$1,066,000 -44% 30 Sep 2020 10-Q 15 Oct 2020 2020 Q3
Q2 2020 $1,649,000 -$1,050,000 -39% 30 Jun 2020 10-Q 05 Aug 2020 2020 Q2
Q1 2020 $1,917,000 -$1,034,000 -35% 31 Mar 2020 10-Q 07 May 2020 2020 Q1
Q4 2019 $2,182,000 +$2,182,000 31 Dec 2019 10-K 04 Feb 2021 2020 FY
Q3 2019 $2,443,000 30 Sep 2019 10-Q 14 Nov 2019 2019 Q3
Q2 2019 $2,699,000 30 Jun 2019 10-Q 13 Aug 2019 2019 Q2
Q1 2019 $2,951,000 31 Mar 2019 10-Q 10 May 2019 2019 Q1
Q4 2018 $0 31 Dec 2018 10-K 18 Feb 2020 2019 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.